|
3.1.1 Tabac - e-cigs
|
|
|
Long-term vaping 'far safer than smoking' says 'landmark' study [NHS Choices]
|
|
|
|
|
|
The
findings of this study do appear to reassure that use of e-cigarettes
and nicotine replacement therapy – while continuing to provide nicotine –
can reduce exposure to toxic chemicals that can lead to cancer in
cigarette smokers. However, this is only if you completely stop smoking –
using e-cigarettes or NRT while continuing to smoke won’t help.
|
|
|
|
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
|
Too few U.S. teens getting flu and cancer vaccines [Reuters]
|
|
|
|
|
|
Under
2017 changes to U.S. vaccine recommendations released this week,
children may receive the HPV vaccine starting at age 9 and they may only
need two doses. If they start getting the HPV shots at age 15 or older,
teens will still need three doses.
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
Scientists discover why some cancers may not respond to immunotherapy [UCLA]
|
|
|
|
|
|
UCLA
scientists have discovered that people with cancers containing genetic
mutations JAK1 or JAK2, which are known to prevent tumors from
recognizing or receiving signals from T cells to stop growing, will have
little or no benefit from the immunotherapy drug pembrolizumab. This
early-stage research has allowed them to determine for the first time
why some people with advanced melanoma or advanced colon cancer will not
respond to pembrolizumab, an anti-PD-1 treatment.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment [The Street]
|
|
|
|
|
|
The
Paris-based biotech received an Investigational New Drug, or IND,
approval from the U.S. Food and Drug Administration on Monday to conduct
phase I clinical trials with UCART123, the biotech's gene-edited
product candidate, in patients with acute myeloid leukemia, or AML, and
blastic plasmacytoid dendritic cell neoplasm, or BPDCN.
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
Europe Cancer Immunotherapy Market Report 2017 [ReportsnReports]
|
|
|
|
|
|
This
report studies sales (consumption) of Cancer Immunotherapy in Europe
market, especially in Germany, France, UK, Russia, Italy, Spain and
Benelux, focuses on top players in these countries, with sales, price,
revenue and market share for each player in these Countries.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
FDA lifts clinical hold on Northwest Bio cancer vax trial [FierceBiotech]
|
|
|
|
|
|
Northwest
Bio thinks it will take several months for the trial to reach the
overall survival threshold, and that the routine checks and cleaning
that are performed before the database is closed will be “a multi-month
process.” As such, it is unclear when Northwest Bio will present data
from the trial.
|
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|
Dispute over the legal rights to an anticancer agent continues [C&EN]
|
|
|
|
|
|
In
2014, Kim Janda of Scripps Research Institute California discovered
that ONC201, a drug candidate under development at Oncoceutics, had been
patented with an incorrect chemical structure. Scripps applied for a
new patent on the compound with the correct structure and licensed it to
another company, Sorrento Therapeutics.
|
|
|
|
|
|